Unveiled at the 2022 BIO International Convention, the group's third annual diversity, equity, and inclusion report spotlights improvements both made and needed.
The online pharma event will address the COVID-19 pandemic’s impact on the industry (and vice versa) and innovation in the face of formidable challenges.
Research into Alzheimer’s disease is suffering from a chronic lack of investment, after clinical trial failures across the field, a report by BIO suggests.